 |
Reliable & Innovative Solutions for Transgenesis| home | contact us | |
Investors relations |
| |
|
|
 |
Investors relations |
|
See all
-
The genOway Share
-
Share Price
Stock Market : Alternext – Nyse Euronext
Ticker : ALGEN
Code ISIN : FR004053510
Number of outstanding shares : 5 578 746
First day of trading : May 7, 2007
Share –liquidity contracts
Only available in french
December 31, 2007
July 1, 2008
Shareholders
Dassault Développement : 20.81 %
CDC Entreprises Inno : 19.95 %
Siparex : 12.49 %
Finoway : 9.24 %
Alexandre Fraichard : 4.75 %
Gilles de Poncins : 3.38 %
Rhône-Alpes Création : 2.02 %
Venture capital investors and Managers 72,64%
Public : 27, 36%
-
Financial Calendar
-
Annual results for 2009: April 14, 2010
2009 Annual results Presentation Meeting (SFAF): April 15, 2010
Midcap Gilbert Dupont – Health Seminar: May 18, 2010
Annual General Meeting: June 7, 2010
Half-year results 2010: October 1st 2010
2010 Half-year results Presentation Meeting (SFAF): October 4, 2010
Final year ending: December 31, 2010
Contacts
Investors relations
Please contact us at: finances@genoway.com
Analyst
Guillaume Cuvillier at Gilbert Dupont
+ 33 (0) 1 40 22 41 72
guillaume.cuvillier@gilbertdupont.fr
Please note that any opinions, estimates or forecasts regarding genOway performance made by this analyst are his alone and do not represent opinions, forecasts or predictions by genOway or its management team. genOway referencing of analyses provided by Gilbert Dupont does not imply its endorsement of the information, conclusions or recommendations contained therein.
Requests for copies of analyst reports should be directly addressed to the above-mentioned analyst and institution.
-
Financial Press Releases
-
18 February 2010: genOway and Cellectis close their disagreement
21 December 2009: genOway chosen by Tufts University for major framework contract
15 December 2009: genOway : 2 years renewable framework agreement with the University of Pittsburgh, 6th U.S. research center (Only available in french)
7 December 2009: genOway announces important Framework agreement with BIDMC, Harvard Medical School's Teaching Hospital
13 November 2009: genOway will appeal the decision of the TGI of November 12, 2009 (Only available in french)
4 November 2009: genOway announces important framework agreement with UPenn (University of Pennsylvania) one of the top ten U.S universities
29 October 2009: genOway launches its "Knock-in 2in1" technology based on its proprietary "StemCell HY" platform.
20 October 2009: genOway acquires exclusive license for Flex technology developed by Professor Pierre Chambon and Dr. Norbert Ghyselinck at the IGBMC
30 September 2009: genOway annouces its half year results for 2009 (Only available in french)
10 September 2009: genOway’s expertise selected as part of the AD-Inov consortium
2 September 2009: genOway: strong growth of academic customer portfolio in the first semester of 2009
14 May 2009: genOway reports the expansion of its business with major biopharmaceutical companies in first quarter of 2009
6 April 2009: genOway annouces its financial results for 2008 (Only available in french)
11 February 2009: genOway introduces StemCellHY, a new production technology
13 January 2009: genOway announces a 2-year general agreement with the renowned IMM - University of Zurich
06 January 2009: genOway launches a legal action against Cellectis S.A. and claims several millions euros for compensation
29 September 2008: genOway annouces its half year results for 2008 (Only available in french)
9 June 2008: Project IT- DIAB : genOway obtains € 1.1 million funding from OSEO and the exclusive distribution of the research models created
7 April 2008: genOway announces its financial results for 2007. (Only available in french)
2 April 2008: genOway signs a major master services agreement with the Japanese pharmaceuticals leader Eisai Co. Ltd.
25 March 2008: genOway : master service agreement with Boehringer Ingelheim Pharmaceuticals Inc.
19 November 2007 : genOway launches standardized genetically modified mousse and rat research models
17 October 2007 : genOway signs a contract for up to 2 Million USD in intended services with a US-based leading biopharmaceutical firm
19 September 2007: genOway annouces its half year results for 2007 (Only available in french)
May 2007: genOway is successfully entering the stock market: Capital raised will accelerate the transgenic company's technological innovation and industrialization process (Only available in french)
23 March 2007: genOway annouces its financial results for 2006 (Only available in french)
-
Annual reports / Registration Documents
-
Annual report 2008 Only available in french
Can be downloaded here
Annual report 2007 Only available in french
Can be downloaded here
IPO prospectus Only available in french
Can be downloaded here
-
Shareholder's Documentation
-
Annual Shareholder's meeting, june 8 , 2009
Documentation only available in french
Annual Shareholder's Meeting, june 26, 2008
Documentation only available in french
|
|
|
|
|
Transgenics (rat and mouse gene modification): knockout mouse (KO mouse), knock in mice (KI mice) and transgenic mouse
genOway, service provider in transgenesis for customized genetically modified mice and rats: gene overexpression, gene knockdown, gene knockout, etc.
| Site map | Legal Notice | © genOway 2006 |
|
|
Service offer
Investors relations